Adaptimmune Therapeutics PLC
ADAPY· OTC
ADAPYAdaptimmune Therapeutics PLC
Who holds Adaptimmune Therapeutics PLC, from the managers’ Form 13F reports for the quarter ended Mar 31, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Rhumbline Advisers | 3.7K | ±0% | $72 | 0% | May 12, 2026 |
